Selective expression of trophoblastic hormones by lung carcinoma: neurendocrine tumors exclusively produce human chorionic gonadotropin alpha-subunit (hCGalpha).

Recent findings suggest that glycoprotein- and protein hormones act as local auto/paracrine growth/differentiation factors in normal and malignant tissue. An imbalanced or even selective production of human chorionic gonadotropin-alpha (hCGalpha) by neuroendocrine tumors in various organs has been reported. In this context, the ectopic production of trophoblastic hormones by lung carcinoma has not been investigated systemically. Because the determination of serum levels of hCGalpha are flawed by a number of factors, we designed an immunohistochemical study to precisely assess the comprehensive paraneoplastic auto-/paracrine hormone production by lung carcinoma of various histological types. To this end, 90 patients with primary lung neoplasms (40 neuroendocrine tumors, 29 adenocarcinomas, 20 squamous cell carcinomas, and 1 adenosquamous carcinoma) were analyzed by our well characterized monoclonal antibodies (mabs) against the glycoprotein hormones hCG, and its derivatives hCGalpha, hCGbeta, hCGbeta core-fragment (hCGbetacf), luteinizing hormone (LH, LHbeta), follicle-stimulating hormone (FSH, FSHbeta), and the protein hormones placental lactogen (PL) and growth hormone (GH). Overall, trophoblastic hormone immunoreactivity was found in 31% (28/90) of all lung carcinomas, regardless of histological differentiation. Detailed analysis showed 23% (21/90) hCGalpha-, 7% (6/90) hCGbeta, and 2% (2/90) hCGbetacf-positive cases. The tumors produced neither the intact heterodimer hCG, nor the other placental protein hormones PL-A/B and GH-V, or the hCG-related pituitary gonadotropins FSH/FSHbeta and LH/LHbeta. With regard to histological differentiation, it appeared that neuroendocrine tumors exclusively produced free hCGalpha in a distinct expression pattern depending on histological tumor grade. Thirty-eight percent (15/40) of all neuroendocrine neoplasms were hCGalpha-positive, and marker positivity increased with more mature, highly differentiated tumors (20% of small cell neuroendocrine carcinomas versus 90% of atypical and typical carcinoids). This is in striking contrast not only to trophoblastic malignancies and testicular germ cell tumors, but also to nontrophoblastic tumors, such as gynecological and urothelial malignancies, 60% of which produce hCGbeta and where marker positivity correlates with poor histological tumor differentiation. In conclusion, free hCGalpha, but not hCGbeta, is a useful marker for neuroendocrine differentiation in primary lung tumors. The fact that it is preferentially produced by the differentiated tumor types (carcinoids) points to a putative biological function in these tissues. The few hCGbeta-positive NSCLC must not be confounded with primary mediastinal choriocarcinoma.